Article
The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.
British journal of haematology - 1 Oct 2010
Best O Giles, Singh Nisha, Forsyth Cecily, Mulligan Stephen P
Abstract excerpt
Inhibitors of heat-shockprotein 90 (Hsp90) have been proposed as a novel therapeutic option for Chronic Lymphocytic Leukaemia (CLL), particularly as their mechanism of action appears independent of mutations of ATM or TP53. We investigated the activity of a novel Hsp90 inhibitor, SNX7081, against a panel of eight haematological cell lines and 23 CLL patient samples. SNX7081 displayed significant effects on cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.